Spirits were not necessarily high among Duchenne muscular dystrophy patients and advocates heading into FDA’s advisory committee meeting on BioMarin Pharmaceutical Inc.’s drisapersen.
After reviewing FDA’s largely negative meeting briefing document, many of the attendees at the Nov. 24 Peripheral and Central Nervous...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?